07 July 2015 | Analysis | By BioSpectrum Bureau
China's CSPC Pharma has a rich product pipeline
CSPC PHARMACEUTICAL GROUP, China
Chairman: Mr CAI Dongchen
Revenue: $1358.3 mn
Business: Manufacturers of generics, bulk drug, innovative drugs
In 2014, CSPC Pharmaceutical clocked profit of $163 million, representing an increase of 30.4 percent over the last year. The company continued to invest in academic research and innovative drugs. The existing product line marked sales revenue of $351.1 million, representing an increase of 44.9 percent from the previous year.
In 2014, the antibiotics business picked up at steady rate and the company continued to capitalize its technological advantages in drug research and development.
CSPC Pharmaceutical's existing oncology drug products include Duomeisu (anthracycline used as a first-line chemotherapy), Jinyouli (used for the prevention of leucopenia and infection induced by chemotherapy) and Ailineng (for the treatment of nerve glioma and brain metastase).
The group has over 170 products under R&D, with focus on areas likecardio-cerebrovascular, diabetes, oncology, neurology and anti-infective. Among these products, 14 are Class I new drugs and 46 are Class III new drugs (of which 33 products are among the first three applications). Five of the 14 Class I new drugs are under clinical trial.
CSPC Pharmaceutical has submitted applications for 34 drugs with the China Food and Drug Administration in 2014 of which, nine are production applications and 25 are clinical trial applications. During the year, the group obtained production approvals for six products in China.